Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.52 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8986023 | 1.00 | DRD2 (0.64) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL16249345 | 0.93 | DRD2 (0.67) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL29090112 | 0.88 | DRD2 (0.72) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL654604 | 0.81 | DRD2 (0.86) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL6752708 | 0.79 | ESR1 (0.64) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL6058583 | 0.79 | ESR1 (0.64) | DRD2OPRM1MEN1KMT2ASLC6A4 | |
| SCHEMBL216848 | 0.78 | DRD2 (0.60) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL17186803 | 0.78 | DRD2 (0.60) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL187716 | 0.78 | DRD2 (1.00) | DRD2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL24845287 | 0.78 | DRD2 (0.43) | DRD2OPRM1OPRL1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210005814-A1 | MATERIAL FOR HOLE-TRANSPORT LAYER, MATERIAL FOR HOLE-INJECTION LAYER, ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210005814-A1 | MATERIAL FOR HOLE-TRANSPORT LAYER, MATERIAL FOR HOLE-INJECTION LAYER, ORGANIC COMPOUND, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC DEVICE, AND LIGHTING DEVICE | SLC18A1, AOC3, HTR3D | DRD2 39/4885OPRM1 191/4885OPRL1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.